JP2002531135A5 - - Google Patents

Download PDF

Info

Publication number
JP2002531135A5
JP2002531135A5 JP2000586931A JP2000586931A JP2002531135A5 JP 2002531135 A5 JP2002531135 A5 JP 2002531135A5 JP 2000586931 A JP2000586931 A JP 2000586931A JP 2000586931 A JP2000586931 A JP 2000586931A JP 2002531135 A5 JP2002531135 A5 JP 2002531135A5
Authority
JP
Japan
Prior art keywords
attenuated bacterium
immunizing
medicament
manufacture
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000586931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531135A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA1999/001151 external-priority patent/WO2000034498A1/en
Publication of JP2002531135A publication Critical patent/JP2002531135A/ja
Publication of JP2002531135A5 publication Critical patent/JP2002531135A5/ja
Pending legal-status Critical Current

Links

JP2000586931A 1998-12-04 1999-12-02 クラミジア感染に対する２段階免疫感作法 Pending JP2002531135A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11085598P 1998-12-04 1998-12-04
US60/110,855 1998-12-04
PCT/CA1999/001151 WO2000034498A1 (en) 1998-12-04 1999-12-02 Two-step immunization procedure against chlamydia infection

Publications (2)

Publication Number Publication Date
JP2002531135A JP2002531135A (ja) 2002-09-24
JP2002531135A5 true JP2002531135A5 (OSRAM) 2007-02-08

Family

ID=22335290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000586931A Pending JP2002531135A (ja) 1998-12-04 1999-12-02 クラミジア感染に対する２段階免疫感作法

Country Status (10)

Country Link
US (6) US6676949B2 (OSRAM)
EP (1) EP1169465B1 (OSRAM)
JP (1) JP2002531135A (OSRAM)
AT (1) ATE318924T1 (OSRAM)
AU (1) AU772356B2 (OSRAM)
CA (1) CA2366462C (OSRAM)
DE (1) DE69930147T2 (OSRAM)
MX (1) MXPA01005615A (OSRAM)
NZ (1) NZ512730A (OSRAM)
WO (1) WO2000034498A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU772356B2 (en) * 1998-12-04 2004-04-22 Aventis Pasteur Limited Two-step immunization procedure against chlamydia infection
DE60044146D1 (de) * 1999-12-22 2010-05-20 Aventis Pasteur D ihre verwendungen
WO2002078735A2 (en) * 2001-03-29 2002-10-10 Mcgill University Leishmania vaccines
CA2504938C (en) * 2002-11-07 2011-10-11 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
US20070060904A1 (en) * 2005-03-14 2007-03-15 Becton, Dickinson And Company Filling system and method for syringes with short needles
CA2787697C (en) 2009-01-29 2018-03-20 British Columbia Cancer Agency Branch Compositions comprising chlamydia antigens
US10258682B2 (en) 2013-01-16 2019-04-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Attenuated chlamydia vaccine

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US5643771A (en) * 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
DE3650571T2 (de) 1985-01-14 1997-02-27 Chiron Corp Hauptprotein der Aussenmembran von Chlamydia
US5770714A (en) 1985-01-14 1998-06-23 Washington Research Foundation Chlamydia major outer membrane protein
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5869608A (en) * 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
JP3004049B2 (ja) * 1989-03-31 2000-01-31 ワシントン ユニバーシティー 病原性のないｐｈｏＰ型微生物を含有するワクチン
GB8912330D0 (en) * 1989-05-30 1989-07-12 Wellcome Found Live vaccines
TW201794B (OSRAM) * 1991-05-03 1993-03-11 American Cyanamid Co
US5840297A (en) * 1993-03-19 1998-11-24 Johns Hopkins University Vaccine comprising anti-idiotypic antibody to chlamydia GLXA and process
NZ276874A (en) * 1993-11-03 1997-11-24 Pfizer Vaccine for treating chlamydia comprising a major outer membrane protein and lipopolysaccharide preparation from a chlamydia organism
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US5877159A (en) * 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US6682729B1 (en) * 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
GB9516293D0 (en) * 1995-08-09 1995-10-11 Immunova Ltee Novel peptides and their use as vaccines
US6001372A (en) * 1995-08-25 1999-12-14 Wisconsin Alumni Research Foundation Antigenic peptides of Chlamydia trachomatis
WO1997044446A1 (en) * 1996-05-24 1997-11-27 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US6696421B2 (en) * 1996-07-12 2004-02-24 University Of Manitoba DNA immunization against chlamydia infection
DE69734882T2 (de) * 1996-07-12 2006-08-17 University Of Manitoba, Winnipeg Dna immunisierung gegen chlamydia infektion
US6235290B1 (en) * 1997-07-11 2001-05-22 University Of Manitoba DNA immunization against chlaymdia infection
US6344202B1 (en) * 1996-07-12 2002-02-05 University Of Manitoba DNA immunization against chlaymdia infection
US6180398B1 (en) * 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
US6464979B1 (en) * 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
JP2002513287A (ja) * 1997-04-18 2002-05-08 ゲゼルシャフト フュア バイオテクノロギッシェ フォーシュンク エム ベー ハー（ゲー ベー エフ） サルモネラ株
US5935816A (en) * 1997-07-23 1999-08-10 Smithkline Beecham Corporation Chlamydia trachomatis lysS polynucleotides
US6605287B2 (en) * 1997-08-28 2003-08-12 Board Of Supervisors Of Louisiana State University & Agricultural And Mechanical College Vaccines for Chlamydia psittaci infections
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
ES2352082T3 (es) * 1997-11-21 2011-02-15 Merck Serono Biodevelopment Polipéptido de la membrana externa de chlamydia pneumoniae, fragmentos del mismo y sus usos, en particular para el diagnóstico, la prevención y el tratamiento de una infección polipéptido de la membrana externa de chlamydia pneumoniae, fragmentos del mismo y sus usos, en particular para el diagnóstico, la prevención y el tratamiento de una infección.
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
US20020064517A1 (en) * 1998-04-30 2002-05-30 Stewart A. Cederholm-Williams Fibrin sealant as a transfection/transformation vehicle for gene therapy
US6190669B1 (en) * 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
US20030147924A1 (en) * 1998-07-27 2003-08-07 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding dna fragments and uses thereof
US6660275B2 (en) * 1998-07-27 2003-12-09 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
AU4793499A (en) * 1998-07-27 2000-02-21 Aventis Pasteur Limited (chlamydia) antigens and corresponding dna fragments and uses thereof
US6686339B1 (en) * 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
WO2000011181A1 (en) * 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6693087B1 (en) * 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6649370B1 (en) * 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6403101B1 (en) * 1998-10-28 2002-06-11 Connaught Laboratories Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6872814B2 (en) * 1998-10-29 2005-03-29 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) * 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
CA2353107A1 (en) * 1998-12-01 2000-06-08 Andrew D. Murdin Chlamydia antigens and corresponding dna fragments and uses thereof
AU772356B2 (en) * 1998-12-04 2004-04-22 Aventis Pasteur Limited Two-step immunization procedure against chlamydia infection
US6448234B1 (en) * 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US7297341B1 (en) * 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2354431A1 (en) * 1998-12-23 2000-07-06 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6808713B1 (en) * 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
AU774902B2 (en) * 1998-12-28 2004-07-15 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2365196C (en) * 1999-03-12 2011-11-15 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
EP1177301B1 (en) * 1999-05-03 2007-10-10 Sanofi Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6225443B1 (en) * 1999-05-19 2001-05-01 Wisconsin Alumni Research Foundation Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
US6191259B1 (en) * 1999-05-19 2001-02-20 Wisconsin Alumni Research Foundation Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
US6811783B1 (en) * 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic
EP1220925B8 (en) * 1999-09-20 2008-04-23 Sanofi Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) * 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001036455A2 (en) * 1999-11-12 2001-05-25 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
AU2138501A (en) * 1999-12-22 2001-07-03 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2138601A (en) * 1999-12-22 2001-07-03 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
DE60044146D1 (de) * 1999-12-22 2010-05-20 Aventis Pasteur D ihre verwendungen
US20020082402A1 (en) * 2000-04-04 2002-06-27 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020071831A1 (en) * 2000-04-04 2002-06-13 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020132994A1 (en) * 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20030100706A1 (en) * 2000-04-04 2003-05-29 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094965A1 (en) * 2000-04-04 2002-07-18 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20040254130A1 (en) * 2000-05-08 2004-12-16 Murdin Andrew D Chlamydia antigens and corresponding dna fragments and uses thereof
JP3653219B2 (ja) * 2000-10-30 2005-05-25 シャープ株式会社 印刷装置およびそれを用いた通信装置または情報処理装置
US8053568B2 (en) * 2004-11-30 2011-11-08 Aeras Global Tb Vaccine Foundation Bacterial packaging strains useful for generation and production of recombinant double-stranded RNA nucleocapsids and uses thereof

Similar Documents

Publication Publication Date Title
JP2002511411A5 (OSRAM)
JP2002506648A5 (OSRAM)
JP2004525194A5 (OSRAM)
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
JP2003520232A5 (OSRAM)
JP2002512074A5 (OSRAM)
JP2003503454A5 (OSRAM)
MX9304485A (es) Formulacion solida, oral, de liberacion controlada, que incluye complejos hidrofilicos aglomerados con caracteristicas de liberacion multifasicas.
NZ598367A (en) Multiple vaccination including serogroup C meningococcus
EP1283054A4 (en) MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
JP2001064332A5 (OSRAM)
JP2003506416A5 (OSRAM)
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
EP2275121A3 (en) Protein-based streptococcus pneumoniae vaccines
JP2003513935A5 (OSRAM)
HK1046631A1 (zh) 含有酮替芬的眼药组合物
JP2000159790A5 (OSRAM)
WO2003059385A3 (en) Hiv vaccine and method of use
JP2002531135A5 (OSRAM)
JP2002536525A5 (OSRAM)
WO2001080641A3 (de) Fungizide wirkstoffkombinationen
JP2003504445A5 (OSRAM)
WO2002053149A3 (de) Arzneimittel enthaltend ein polyamin als wirksubstanz
DK1305037T3 (da) Smertestillende medikament
JP2002509169A5 (OSRAM)